Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine

28-09-2024 | Radiotherapy | Original Article

18F-FDG PET/CT biomarkers as predictors of long term outcomes and survival rates in patients with high risk malignant pulmonary masses/nodules treated with stereotactic ablative radiotherapy

Authors: Raef R. Boktor, Salvatore U. Berlangieri, Eddie Lau, Adeline Lim, Sylvia J. Gong, Xia Li, Andrew M. Scott

Published in: Annals of Nuclear Medicine

Login to get access

Abstract

Introduction

Stereotactic ablative body radiotherapy (SABR) is a standard treatment option for patients with malignant pulmonary masses (including primary and metastatic lesions) who are unfit for surgery or who are medically operable but refuse surgery. Flourine-18 flurodeoxyglucose positron emission tomography (18F-FDG PET) volumetric metabolic parameters, i.e., metabolic tumour volume (MTV) and total lesion glycolysis (TLG) play an important role in assessing the biological characteristics of some tumours and its role as potential prognostic factors has also been introduced.

Objectives

The aim of this retrospective study is to assess the value of baseline metabolic volumetric parameters as prognostic imaging biomarkers in patients with pulmonary masses/nodules treated with SABR.

Methods

70 patients were included in this retrospective study (39 male and 31 female, age range 47–91 years, mean 76 years). Standardized uptake value (SUVmax), SUVmean, MTV and TLG for all the patients were calculated on baseline 18F-FDG PET/CT. Patient outcome was divided into 3 categories free of disease, stable disease and disease progression.

Results

There was no significant statistical difference in the SUVmax and SUVmean in all the three categories. Mean SUVmax ranges from 7.13 to 8.08 with its highest value in the stable disease and lowest value in the progressive disease categories. Similarly, the average SUVmean was 4.9 in the free of disease category and 4.68 in the progressive disease category. MTV and TLG were low in the free of disease and the highest in progressive disease. MTV increased from 2.25 cm3 in free of disease category to 3.23 cm3 and 7.29 cm3 in stable disease and progressive disease, respectively. TLG has increased from 11.7 in the disease-free survival category to 18.77 and 40.39 in the stable and progressive disease, respectively. Patients with low MTV had longer overall survival (OS) than patients with high MTV (37 months versus 27 months, p value = 0. 0018). In addition, OS was longer in patients with low TLG (36 months versus 24 months, p value = 0.016).

Conclusions

TLG and MTV are more useful than SUVmax and SUVmean for predicting outcome, OS and progression-free survival (PFS) in patients receiving SABR. The TLG and MTV measurement on 18F-FDG PET imaging may be routinely recommended in baseline 18F-FDG PET/CT prior to SABR.
Literature
1.
Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2010;81:1352–8.CrossRefPubMed
2.
Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:685–92.CrossRefPubMed
3.
Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Stereotactic ablative radiotherapy (SABR) in potentially operable stage I non-small cell lung cancer patients. J Thorac Oncol. 2011;6:S278–9.
4.
Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using 18F-FDG PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159–71.CrossRefPubMed
5.
Roedl JB, Colen RR, Holalkere NS, et al. Adenocarcinomas of the esophagus: response to chemo-radiotherapy is associated with decrease of metabolic tumor volume as measured on 18F-FDG PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2009;89(3):278–86.CrossRef
6.
Benz MR, Allen-Auerbach MS, Eilber FC, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49(10):1579–84.CrossRefPubMed
7.
Paulino AC, Johnstone PA. 18F-FDG PET in radiotherapy treatment planning: Pandora’s box? Int J Radiat Oncol Biol Phys. 2004;59:4–5.CrossRefPubMed
8.
Im HJ, Pak K, Cheon GJ, et al. Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:241–51.CrossRefPubMed
9.
Im HJ, Kim TS, Park SY, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39–49.CrossRefPubMed
10.
Im HJ, Kim YK, Kim YI, Lee JJ, Lee WW, Kim SE. Usefulness of combined metabolic-volumetric indices of 18F-FDG PET/CT for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer. Nucl Med Mol Imaging. 2013;47:36–43.CrossRefPubMed
11.
12.
Nie K, Zhang Y, Nie W, Zhu L, Chen Y, et al. Prognostic value of metabolic tumour volume and total lesion glycolysis measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in small cell lung cancer: a systematic review and meta-analysis. J Med Imaging Radiat Oncol. 2019;63:84–93.CrossRefPubMed
13.
Yanarates A, Yazici B. Volumetric 18F-FDG PET parameters can predict overall survival in advanced lung adenocarcinoma. Rev Esp Med Nucl Imagen Mol. 2020;39(1):3–8.PubMed
14.
Zaizena Y, Azuma K, Kurata S, Sadashima E, Hattori S, et al. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. Eur J Radiol. 2012;81:4179–84.CrossRef
15.
Yıldırım F, Yurdakul AS, Özkaya S, Akdemir ÜÖ, Öztürk C. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer. Clin Respir J. 2017;11:602–11.CrossRefPubMed
16.
Budaka Emine, et al. The prognostic role of 18F-FDG PET/CT in small-cell lung cancer. Rev Esp Med Nucl Imagen Mol. 2020;39(1):9–13.
17.
Imamura Y, Azuma K, Kurata S, Hattori S, Sasada T, Kinoshita T, et al. Prognostic value of SUVmax measurements obtained by 18F-FDG PET in patients with non-small cell lung cancer receiving chemotherapy. Lung Cancer. 2011;71:49–54.CrossRefPubMed
18.
Nappi A, Gallicchio R, Simeon V, Nardelli A, Pelagalli A, Zupa A, et al. 18F-FDG PET/CT parameters as predictors of outcome in inoperable NSCLC patients. Radiol Oncol. 2015;49:320–6.CrossRefPubMedPubMedCentral
19.
Kurtipek E, Ayci MCY, Düzgün N, Esme H, Terzi Y, Bakdik S, et al. 18F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non–small cell lung cancer. Clin Nucl Med. 2015;40:459–63.CrossRefPubMed
20.
Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2006;64(449–54):29.
21.
Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957patients with NSCLC. J Thorac Oncol. 2010;5:620–30.CrossRefPubMed
22.
UyBico SJ, Wu CC, Suh RD, Le NH, Brown K, Krishnam MS. Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radio-graphics. 2010;30(1163–81):31.
23.
Yoo SW, Kim J, Chong A, Kwon SY, Min JJ, Song HC, et al. Metabolic tumor volume measured by 18F-FDG PET/ CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer. Nucl Med Mol Imaging. 2012;46:286–93.CrossRefPubMedPubMedCentral
Metadata
Title
18F-FDG PET/CT biomarkers as predictors of long term outcomes and survival rates in patients with high risk malignant pulmonary masses/nodules treated with stereotactic ablative radiotherapy
Authors
Raef R. Boktor
Salvatore U. Berlangieri
Eddie Lau
Adeline Lim
Sylvia J. Gong
Xia Li
Andrew M. Scott
Publication date
28-09-2024
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-024-01983-9